Delivery Order SPE2DB22D2007-SPE2DB25FJ3UN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,283.02 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a completion date of July 31, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price pricing and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a competitive delivery order valued at $1,971.30 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. The award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed price transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a contract ceiling value of $2,401.91. This is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, executed without a set-aside designation. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $6,031.38 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (120 mL) on August 13, 2025, with an ultimate completion date of August 14, 2025. This contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $3,527.50 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (120 mL) on August 5, 2025, with completion targeted for August 6, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under a larger indefinite delivery contract vehicle. The product will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,278.86 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 180 ml quantities. This contract award is non-set-aside and utilizes firm fixed pricing under a delivery order contract type, with performance scheduled for completion by September 5, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $2,628.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml). This contract is non-set-aside and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $6,715.87 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in 180 mL quantities. This competitively awarded, firm fixed-price delivery order was issued on September 8, 2025, with an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under a larger vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity, valued at $1,807.02. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The order is scheduled for completion by June 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,154.08 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement action typical of DLA's ongoing medical...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3UNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,544.36 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in 60 mL quantities. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 11, 2025. The product will be sourced from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent contract serves as a comprehensive global pharmaceutical support vehicle that enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide, including support for the Defense Health Agency and U.S. Coast Guard. As a major pharmaceutical distributor, AmerisourceBergen maintains a significant federal contract portfolio with DLA, fulfilling critical medical procurement needs across multiple therapeutic domains for defense and military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 8/8/25 |